Actualités sur Novartis

Medison Pharma; Alnylam Pharmaceuticals

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Zug, Switzerland (ots/PRNewswire) - - The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance - Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient ...

Medison Pharma; Alnylam Pharmaceuticals

Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics

Zug, Switzerland (ots/PRNewswire) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their ...

IDEA Pharma

Pfizer tops the CNS Summit Innovation Index

London (ots/PRNewswire) - The fifth annual ranking of digital, R&D and commercial partnership innovation in global pharma The fifth annual CNS Summit Innovation Index, compiled by IDEA Pharma, sees Pfizer top the industry. Released at the CNS Summit in Boston, MA, the CNS Summit Innovation Index examines which drug makers are leveraging innovation in three spheres: clinical development which sets the stage for future ...

Versameb AG

Versameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials

Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...

Versameb AG

Versameb raises CHF 6.4 million in Seed C round and strengthens the team

Philogen

Philogen Announces EUR62 Million Financing Round

EUR62M funding will be used to progress wholly-owned pipeline products through clinical development and expand manufacturing activities Dr. Guido Guidi, Dr. Roberto Ferraresi and Dr. Roberto Marsella join the board of directors Siena, Italy (ots/PRNewswire) - Philogen S.p.A (or the "Company"), a clinical-stage biotechnology company focused on antibody-based therapeutics, today is pleased to announce a EUR62 million ...

Philogen

Philogen Announces Collaboration

Siena, Italy (ots/PRNewswire) - Philogen S.p.A. (a privately-owned company) today announced that they have entered into a collaboration and license agreement with Novartis to discover and develop a new class of immunomodulatory therapeutics. (Logo: https://mma.prnewswire.com/media/811555/Philogen_Logo.jpg ) "We are extremely pleased to establish a new collaboration with Novartis, a leader in the discovery and development of therapies for cancer patients," commented Dr. ...

BB Biotech AG

DGAP-News: BB Biotech shares hold steady in the second quarter

DGAP-News: BB BIOTECH AG / Key word(s): Half Year Results BB Biotech shares hold steady in the second quarter (news with additional features) 20.07.2018 / 07:00 The issuer is solely responsible for the content of this announcement. Media release as of July 20, 2018 Interim report of BB Biotech AG as of June 30, 2018 BB Biotech shares hold steady in the second quarter - Substantial portfolio adjustments, new investments ...